Hospitalization or Ambulatory Treatment of Acute Diverticulitis

NCT ID: NCT01081054

Last Updated: 2012-06-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

132 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-09-30

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of 01DIVER is to evaluate efficacy and safety of a home treatment protocol for non complicated diverticulitis compared with management in the hospital. The hypothesis is that a ambulatory treatment with oral antibiotic and progressive introduction of diet is not inferior to the conservative management in hospital in patients with acute not complicated sigmoid diverticulitis, shown by contrast enhanced CT scan. Patients are prospectively randomized to conservative antibiotic treatment either to ambulatory or to hospital treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diverticulitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ambulatory Treatment

Patients are treated ambulatory with oral antibiotic for 10 days; for the first five days these patients are contacted by telephone daily to progress oral intake.

Group Type OTHER

Ambulatory versus hospitalisation

Intervention Type OTHER

Patients are treated with the same antibiotic agent, the difference between the two arms is endovenous treatment for hospitalized patients for the first days till oral feeding. The ambulatory group starts directly with orally administered antibiotic treatment.

Hospital treatment

Patients are hospitalized and treated with antibiotic, for the first days by endovenous antibiotic and with diet progression orally.

Group Type ACTIVE_COMPARATOR

Ambulatory versus hospitalisation

Intervention Type OTHER

Patients are treated with the same antibiotic agent, the difference between the two arms is endovenous treatment for hospitalized patients for the first days till oral feeding. The ambulatory group starts directly with orally administered antibiotic treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ambulatory versus hospitalisation

Patients are treated with the same antibiotic agent, the difference between the two arms is endovenous treatment for hospitalized patients for the first days till oral feeding. The ambulatory group starts directly with orally administered antibiotic treatment.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age older than 18 years
* Diagnosis of mild diverticulitis by abdominal computerized tomography
* Signed informed consent

Exclusion Criteria

* Severe diverticulitis
* Informed consent not signed
* Suspicion of colon cancer
* Pneumoperitoneum
* Intolerance for oral feeding
* Antibiotics for diverticulitis in the last month
* Immunosuppression
* Pregnancy or lactation
* Severe (decompensated) other illness
* Psychological or social problems
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital Universitari de Bellvitge

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sebastiano Biondo

S. Biondo, MD, PhD, Colorectal Unit, Department of Surgery

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sebastiano Biondo, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitari de Bellvitge

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Universitari de la Vall d´Hebron

Barcelona, Barcelona, Spain

Site Status

Hospital Universitari Bellvitge, Colorectal Unit

L'Hospitalet de Llobregat, Barcelona, Spain

Site Status

Hospital Universitari de Girona Doctor Josep Trueta

Girona, Girona, Spain

Site Status

Hospital Virgen del Camino

Pamplona, Navarre, Spain

Site Status

Hospital Clinico Universitario De Valencia

Valencia, Valencia, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2008-008452-17

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

01DIVER

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

FMT in Uncomplicated Diverticulitis
NCT05373784 ACTIVE_NOT_RECRUITING EARLY_PHASE1
Asacol Acute Diverticulitis(DIVA)Study
NCT00554099 COMPLETED PHASE2